Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01472991 · ClinicalTrials.gov registry record · Phase 2

Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)

A Phase 2 study, sponsored by Targacept.

Completed
Registry status
Phase 2
Development phase
250
Enrollment target

NCT01472991: Completed Phase 2 study, sponsored by Targacept.

NCT01472991 is a Phase 2 study that has completed, run by Targacept. The registered enrollment target is 250 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01472991, a Phase 2 study, has completed, sponsored by Targacept.

COMPLETED
Registry status
Phase 2
Development phase
250 participants
Enrollment target

Study Summary

Study is to assess if TC-5619 improves symptoms for adults diagnosed with the inattentive-predominant subtype of ADHD over a 4-week treatment period.

Primary Outcome

Scores on the inattentive subscale of the CAARS-INV obtained at Day 1 (baseline) and weeks 2, 4, and 6. Primary comparison will be difference between Day 1 and Week 4 (TC-5619 5mg and 25 mg vs. placebo).

Interventions

  • DRUG Placebo
  • DRUG TC-5619-238 5mg
  • DRUG TC-5619-238 25mg

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2011-11
Est. Completion 2012-07
Phase Phase 2
Targacept

13 total trials

What the finished NCT01472991 record still lists

NCT01472991 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% higher).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01472991 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01472991 about?

NCT01472991 is a clinical study titled "Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)". Study is to assess if TC-5619 improves symptoms for adults diagnosed with the inattentive-predominant subtype of ADHD over a 4-week treatment period.

What is the current status of trial NCT01472991?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2011-11. Estimated completion is 2012-07.

What interventions are being tested in trial NCT01472991?

The interventions under investigation include: Placebo (DRUG), TC-5619-238 5mg (DRUG), TC-5619-238 25mg (DRUG).

Who is sponsoring clinical trial NCT01472991?

This trial is sponsored by Targacept, which has 13 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01472991's enrollment target sits among peer trials

250 222nd of 2000 higher than 1,768 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01472991, the US trial registry maintained by the National Library of Medicine. NCT01472991 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.